On-target site enriching fluorescent bioprobe for imaging of receptor tyrosine kinase in tumor

Meng Gao Jiqiu Yin XianChao Jia Ye Gao Yang Jiao

Citation:  Meng Gao, Jiqiu Yin, XianChao Jia, Ye Gao, Yang Jiao. On-target site enriching fluorescent bioprobe for imaging of receptor tyrosine kinase in tumor[J]. Chinese Chemical Letters, 2025, 36(6): 110297. doi: 10.1016/j.cclet.2024.110297 shu

On-target site enriching fluorescent bioprobe for imaging of receptor tyrosine kinase in tumor

English

  • Receptor tyrosine kinases (RTKs) are the natural and essential messenger of cancer cells to promote communication between cells and participate in many biological regulatory processes, associating with cell growth, motility, differentiation and metabolism, and their overexpression usually occurs to a sequence of events, including cancer cells metastasis and local angiogenesis during tumor progression [1-4]. Molecule fluorescence probes provide a potential modality for differentiating tumor tissues and guiding clinical procedures, which could show a signal response to report relevant cancers focus on RTKs overexpressing, due to their non-invasive nature, structural adaptability, low cost, and real-time monitoring capabilities [5-7]. Despite fluorescent imaging probes exhibit characteristics such as excellent selectivity and distinct optical signals, the maximizing delivery to the on-target site and reducing non-essential exposures to off-target site to reduce total drug injection remains a much-needed core requirement to RTKs imaging in clinical application [8-11]. Consequently, developing a controllable and homogeneous delivery system, which could enable on-target site enrichment to achieve accumulation in RTKs overexpressing cells and is capable of bioimaging for as long as possible under low injection frequency, is still of significant importance [12, 13].

    A controllable and homogeneous host-guest system could be preparation by means of non-covalent interactions, helping encapsulate the guest fluorescent probe in the enriched pore channel of the host, to achieve functional integration of good optical signaling and on-target site enrichment in tumors [14-16]. Linear molecular probes are designed to target RTKs that are highly enriched in tumor cell membranes, and are suitable for lining up on the membrane surface to report better signal response. Metal-organic framework (MOF) could be controlled by ligands and metal nodes to modulate their pore channels, making the extent of MOF easier to match linear molecular probes without affecting the nature idiosyncrasy of the molecule itself. The MOF-based host-guest system could have stable amphiphilicity and non-covalent bond-driven dynamic properties to facilitate functional integration, and the enhanced permeability and retention (EPR) effect of the nanoparticle-sized MOF could pool the fluorescent properties of the guest molecules and the targeting enrichment ability of the host at the tumor site [18, 19]. Notably, the role of metal ions in immunotherapy has been extensively investigated in recent years, and the use of MOF themselves or the composition of metal ions released from them to modulate the immune response could provide unexpected functional additions to the host-guest system [20-23]. Using MOF and fluorescent probe to construct a host-guest system, targeting RTKs overexpressed in cancer cells, could help to achieve on-target site accumulation, improve signaling efficiency, and achieve prolonged bio-imaging under low injection frequency [24].

    Herein, zeolitic imidazolate framework-8 (ZIF-8) and a fluorescent probe SNI, consisting of sunitinib (RTKs inhibitor) and a naphthalimide derivative, were chosen to form a host-guest system SNI@ZIF-8 through non-covalent interactions, which is capable of enrichment in tumor site and rapidly responding to RTKs in biological systems (Scheme 1). The guest probe SNI exhibited good signal response to RTKs in simulated physiological media, with fluorescence emission intensity about 1.7 fold of the initial fluorescence in 5 min, showing high sensitivity, selectivity and photostability. The host ZIF-8 with abundant porosity and high biocompatibility is favorable for the encapsulation of linear molecules and biological applications, and the lower background fluorescence is more conducive to the signal monitoring of the guest molecule. SNI@ZIF-8 exhibited fluorescent signals to RTKs in solvent and was able to image tumor sites for more than 12 h in tumor-bearing mice. The RTKs inhibitor skeleton in SNI and the targeted aggregation of SNI@ZIF-8 lead to elevated Zn2+ concentrations in tumor cells, both of which affect intracellular protein expression and intracellular signaling, with having potential for immunotherapy in clinic. Possessing the advantages of targeting enrichment ability well-defined fluorescent signal and high biocompatibility, the host-guest system SNI@ZIF-8 enabled fluorescent tracking of RTKs on cell membranes, realizing long-time imaging of tumor regions at low injection frequency.

    Scheme 1

    Scheme 1.  (a) Fluorescence recovery mechanism of probe SNI. (b) SNI@ZIF-8 cell imaging diagram of targeting tumors.

    SNI was prepared by a simple three-step organic synthesis, in which the sunitinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR-2) approved by Food and Drug Administration (FDA), and its molecular skeleton as the recognition group is expected to target receptor tyrosine kinases [25, 26]. Naphthalimide was chosen to be the fluorophore, and the hydrophilic morpholine group was introduced into the naphthalene ring of naphthalimide to improve the probe water solubility. The structure of SNI was well characterized by 1H nuclear magnetic resonance (1H NMR), electronspray ionization mass spectrometry (ESI-MS) and 2D NMR analyses (Figs. S1–S6 in Supporting information). Simultaneously, relatively long flexible chain 1, 6-hexylenediamime helps it fold, and thus reduces the background fluorescence [27] as shown in cross signal between Ha of the sunitinib group and Hb of the naphthalimide derivant (Fig. 1b). The good photostability of fluorescent probe is particularly important for application in the actual environment. SNI has relatively stable fluorescence properties in solvents, fluorescence enhanced transformation of SNI was directly observed and the fluorescence intensity titration curve would reach a plateau for at least 5 min after adding VEGFR-2 [28] from 0 to 0.27 µg/mL (Fig. 1c). Molecular docking method was used to determine the conformation of SNI and VEGFR-2, CYS-919 and ASP-1052 could form hydrogen bonds with SNI, and the interaction between these groups is the key factor for SNI to recognize VEGFR-2 [29]. SNI has a distinct selectivity for VEGFR-2 compared to other substances present in cells, including K+, Na+, Ca2+, Mg2+, d-Glu, l-Cys, l-Arg, l-Asp, l-Pro, nitroreductase (NTR), γ-glutamyltranspeptidase (GGT) and glucose, demonstrating the potential of probe SNI for fluorescence recognition in complex cellular environments (Fig. 1d). Sunitinib can specifically target tyrosine kinase activity domain and, VEGFR-2 kinase activity assays was measured by quantitating the amount of ATP correlated with the amount of kinase activity (Table S1 in Supporting information). The half maximal inhibitory concentration (IC50) value was 1.5 ± 0.1 µmol/L (Fig. S19 in Supporting information). The probe SNI maintained an active state as receptor tyrosine kinase inhibitor in complex media, and it can effectively target the VEGFR domain pocket to inactive enzyme and hinder downstream phosphorylation process. SNI has binding with receptor tyrosine kinases as targeting groups at the micromolar concentrations. The binding affinity of the probe SNI specifically make it targeting receptor tyrosine kinases. To summarize, the experimental results described above show that probe SNI is very suitable for imaging RTKs under solvent conditions, which provided basic support for subsequent experiments. In particular, isothermal titration calorimetry (ITC) with a strong binding effect between SNI and ZIF-8, the association constants (Ka) is 7.81 × 106 L/mol, which provided experimental support for further encapsulation [30], verified that SNI is the ideal element for constructing host-guest nanoscale fluorescent probe for its exceptional host-guest matching (Fig. 1e).

    Figure 1

    Figure 1.  (a) Assembly diagram of SNI@ZIF-8. (b) Recognition mechanism of small molecule fluorescent probe. (c) Fluorescence responses of SNI (4 µmol/L) to various concentrations of tyrosine kinase DMSO/HEPES (5.5:4.5, v/v, pH 7.4). Time-dependent probe SNI (4 µmol/L) (red line) and fluorescence response of probe with the addition of VEGFR-2 (black line). F0 is the peak fluorescence intensity of the probe in solvent condition. (d) Fluorescence responses of probe SNI to various interferences and the data were acquired in DMSO/HEPES (5.5:4.5, v/v, pH 7.4) solution. Data are presented as mean ± standard deviation (SD) (n = 3). Stereo views of SNI with VEGFR-2 (PDB: 4AGD). (e) The ITC experiments were performed by an isothermal titration microcalorimeter at atmospheric pressure, giving the Ka and the thermodynamic parameters.

    Constructing host-guest system through SNI could achieve delivery and stable imaging due to the good recognition targeting and signaling response to RTKs. SNI@ZIF-8 was synthesized by one-pot method (Fig. 1a) [31]. Probe SNI, zinc ion and 2-methylimidazole were stirred at room temperature in a mixture of water and DMSO, and the supernatant was obtained after centrifugation. The carrying capacity of the probe SNI was calculated as 0.8 wt% by ultraviolet spectroscopy of supernatant (Figs. S11 and S12 in Supporting information). The particle size before and after loading was 265.3 and 329.5 nm, respectively, and the structure of the particle did not change significantly shown as X-ray diffraction (XRD) (Fig. 2a and Fig. S9 in Supporting information) [32]. N2 adsorption-desorption experiment (Fig. 2b) further confirmed the successful loading of SNI [33]. The decrease of pore capacity indicates that SNI enter the pore of ZIF-8 and the loading behavior has little effect on the pore size of ZIF-8. Compared with unloaded ZIF-8, the characteristic peaks of SNI were shown in the infrared spectra, solid ultraviolet spectra and X-ray photoelectron spectroscopy (XPS) spectra of SNI@ZIF-8 (Figs. 2c and d, Fig. S15 in Supporting information), which further proved the successful loading of SNI [34]. It is demonstrated that SNI@ZIF-8 had good stability, enabling to be further applied. The release of SNI triggered by the enzyme was detected by incubating RTKs with SNI@ZIF-8 (Fig. 2e). Shaking the dialysis bag of SNI@ZIF-8, samples were taken at intervals to detect the fluorescence intensity of the solution, which could help to compare whether the presence of RTKs triggers the release of guest molecules within the host-guest system. The experimental results showed that the addition of RTKs in the host-guest system can trigger the release of SNI and lead to increased fluorescence intensity. The fluorescence signal providing capability of SNI@ZIF-8 was evaluated by adding RTKs to SNI@ZIF-8 and observing the fluorescence changes in the mixed system (Fig. 2e). The results showed that the fluorescence intensity appeared immediately after the addition of VEGFR-2 in SNI@ZIF-8, indicating that the addition of SNI in ZIF-8 could provide certain targeting effect for nanoparticles. With the extension of incubation time, the fluorescence intensity of the system also gradually increased, indicating that VEGFR-2 gradually adsorbed the SNI in the ZIF-8 channel and realized the detection in a long time. In Fig. 2f, the shape of peaks attributable to VEGFR-2 had little change, and the circular dichroism (CD) value had increased before and after adding SNI, suggesting the secondary and tertiary structures of VEGFR-2 preserved and the intermolecular interaction between receptor tyrosine kinase and SNI [35]. It is certificated that the interaction between VEGFR-2 and SNI is conducive to the removal of SNI from the spatial structure of ZIF-8 and the specific recognition between SNI and receptor tyrosine kinase VEGFR-2.

    Figure 2

    Figure 2.  (a) Dynamic laser light scattering of SNI@ZIF-8 (blue) and ZIF-8 (red) with their scanning electron microscope pictures. Scale bar: 100 nm. (b) N2 quantity and pore volume of ZIF-8 or SNI@ZIF-8. (c) Infrared spectroscopy (IR) spectra of SNI (orange), ZIF-8 (blue), and SNI@ZIF-8 (mazarine). (d) XPS spectra of SNI@ZIF-8, 531.65 eV is O peak of SNI@ZIF-8. (e) The fluorescence intensity of SNI@ZIF-8 incubated with VEGFR-2 in DMSO/HEPES (5.5:4.5, v/v, pH 7.4) solution changed with time (0–70 min), inset shows fluorescence intensity versus the concentrations of SNI. Inset shows the release of SNI in the presence (black) or absence (red) of the enzyme. (f) CD spectra of VEGFR-2 (200 µg/mL) with the increasing addition of SNI from 0 to 1.2 µmol/L. Inset shows CD values at 210 nm versus the concentrations of SNI.

    The results of cytotoxicity tests showed that SNI@ZIF-8 had high biocompatibility, indicating its potential biological application (Fig. S18 in Supporting information) [36]. Flow cytometry enabled rapidly collecting the multifaceted characteristics information from a large cell population and sort out specific cells. A single cell suspension was prepared using HT-29 cells, and the cell concentration was adjusted to 2 × 106/mL. HT-29 cells were divided into test group and control group, cells of test group treated with 1, 2, 5 µmol/L SNI and 40, 80, 200 µg/mL SNI@ZIF-8 were incubated for 40 min and were washed 3 times by PBS buffer, and the intensity of emission and the amount of stained cells were recorded by flow cytometry (Fig. 3a) [37]. In the presence of SNI and SNI@ZIF-8, the geometric mean of the fluorescence intensity showed considerably elevation. Whether SNI@ZIF-8 could be applied to image cell membrane region was confirmed by co-stain HT-29 cells dealing with a dye DIO (3, 3′-dioctadecyloxacarbocyanine perchlorate). The cells were prepared by incubation with DIO (1 µmol/L, green channel) and SNI (0.5, 1 and 2 µmol/L, red channel) for 5 min in PBS buffer [38]. Cell confocal imaging results were consistent with flow cytometry results. As shown in Fig. 3b and Fig. S20 (Supporting information), the curve fitting of the two channels was conducted and the distribution of fluorescence intensity was basically similar. Meanwhile, with the increase of SNI concentration, the mean fluorescence intensity of cells also increased gradually. Note that the green fluorescence images matched well with the red fluorescence images in HT-29 cells, respectively. The membrane localization ability of SNI@ZIF-8 was evaluated, co-localization staining of HT-29 cells was performed for 5 min using DIO (1 µmol/L, green channel) and SNI@ZIF-8 (20, 40 and 60 µg/mL, red channel). As shown in Fig. 3b and Fig. S21 (Supporting information), the fluorescence distribution of red and green channels was basically the same, and the cell fluorescence intensity increased with the increase of SNI@ZIF-8 concentration (Fig. 3c), which had a good co-localization effect with commercially fluorescent dye DIO. SNI@ZIF-8 showed local accumulation of the generated signal and specially located in the plasma membrane distribution. Exploring the cell endocytosis and the targeting of host-guest system is the one should be focus of attention. The cells were treated with the same concentration of ZIF-8 and SNI@ZIF-8 respectively, and the accumulation of zinc ions in the cells was detected to characterize the enhancement of the targeting effect of SNI on the host-guest system. And the inductively coupled plasma-mass spectrometry (ICP) result further indicated that SNI@ZIF-8 is more easily ingested by cells, which further verifies the targeting property of SNI@ZIF-8 (Fig. 3c) [39, 40]. Small molecule inhibition of tyrosine kinases was designed by inhibiting intracellular regions of adenosine triphosphate (ATP) binding sites [41]. Other types of inhibitors competed with molecular skeleton binding sites to inhibit HT-29 cell recognition via SNI@ZIF-8. The fluorescence intensity decreased after the addition of gefitinib and sorafenib (VEGFR inhibitor), which was not significantly different from that of axitinib and erlotinib (epidermal growth factor receptor inhibitor) (Fig. 3d). As shown experimentally, SNI@ZIF-8 achieved targeted enrichment and stable cell membrane imaging in overexpressing RTKs cells. Moreover, SNI with a Sunitinib skeleton demonstrated similar effects to RTKs inhibitors in inhibiting downstream VEGF-A protein expression, and SNI@ZIF-8, which contained zinc ions, exhibited the ability to affect the intracellular caspase-1 signaling pathway (Figs. S23, S24 and S30 in Supporting information) [42-45]. Consequently, the host-guest system SNI@ZIF-8 had excellent biocompatibility and imaging capabilities within HT-29 cells, supporting its participation in cellular immunotherapy as an integrated imaging and therapeutic host and client system.

    Figure 3

    Figure 3.  (a) Flow cytometry treated with different concentrations of SNI and SNI@ZIF-8. (b) Imaging of HT-29 cells treated with 2 µmol/L SNI or 60 µg/mL SNI@ZIF-8. (c) Cell uptake assay by ICP-MS. (d) Relative fluorescence intensity for the HT-29 cells after treatment with gefitinib, erlotinib, axitinib and sorafenib. (e) Hemolysis tests of ZIF-8 and SNI@ZIF-8. Data are presented as mean ± SD (n = 3).

    Hemolysis test was used to evaluate the possibility of application of host-guest system in vivo. As shown in Fig. 3e, ZIF-8 and SNI@ZIF-8 could not cause a lot of destruction of red blood cells, which proved that host-guest system SNI@ZIF-8 is suitable for application in life system. As shown in Fig. 4a, a xenografted mouse model was used to further assess its capability for the real-time visualization of RTKs [46, 47]. Animal experiments were approved by the Biological and Medical Ethics Committee of Dalian University of Technology. The 100 µL HT-29 cell suspensions with cell density of 1 × 107/mL were subcutaneously injected to 5–8 weeks old BALB/c-nu nude mice with equal volume to establish xenograft model. All of the mice received injection of the cancer cells in the outside of armpits, after 10–15 days the tumors were allowed to grow to 400–800 mm3 established the animal model of HT-29 transplanted. The HT-29 transplanted mice received intravenous injections the probe SNI (100 µmol/L, 100 µL) and SNI@ZIF-8 (4 mg/mL, 100 µL) into the cancer and fluorescence signal were monitored for 0.5, 2, 4, 6, 12 and 24 h time interval [48]. Both probes exhibited steadily enhanced fluorescence signals over time for 6 h, and the fluorescence signals were not obvious after 24 h. Moreover, the nanosizing of SNI enabled the nanoprobe to accumulate at the tumor site for a longer time and release the small molecule probe SNI, making it obtain a longer fluorescence signal in mice than SNI (Fig. 4b). Ex vivo fluorescence images of tissue which is dissected from xenografted mouse model, show that tumor still displayed strong fluorescence signal and no fluorescence signal was obtained from heart, spleen and lung (Fig. 4c). Hematoxylin-eosin (H & E) staining showed no significant histopathological damage in major organs of mice injected with SNI and SNI@ZIF-8 (Fig. 4d) [49]. These results indicated that host-guest system SNI@ZIF-8 selectively accumulated tumor tissues and low background fluorescence signal was obtained from other normal organs. Hence, SNI@ZIF-8 can be employed to identify and visualize in biosystems for clearly located tumor, the SNI@ZIF-8 has the ability for real-time imaging tumor tissues [17].

    Figure 4

    Figure 4.  (a) Imaging diagram of SNI@ZIF-8 at the tumor site. (b) In vivo fluorescence imaging of the HT-29 tumor mouse model at different time interval. The fluorescence signal was collected at 570 nm. (c) Ex vivo image of the heart, liver, spleen, lung, kidney and tumor fluorescence of HT-29 tumor mouse model with the probe SNI@ZIF-8 (4 mg/mL, 100 µL) at different time interval (0, 2, 4 and 6 h). (d) H & E staining maps of major organs tissues of mice treated with SNI, ZIF-8 and SNI@ZIF-8. Scale bar: 200 µm.

    In summary, the host-guest system SNI@ZIF-8 has been proposed and constructed as a fluorescent probe that can interact with RTKs on the cell membrane. SNI@ZIF-8 exhibits high selectivity and photostability to VEGFR-2 in simulated physiological media with excellent fluorescence emission response. SNI@ZIF-8 is able to accurately locate the VEGFR-2 overexpressed cancer cells and accumulate in these cells, enabling fluorescence imaging for effectively distinguishing tumor tissues with low background interference in tumor-bearing mice. Prospectively, the host-guest system SNI@ZIF-8 provides a reliable means for recognizing RTKs in early diagnosis, monitoring and prognosis of cancer.

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Meng Gao: Writing – original draft, Data curation. Jiqiu Yin: Methodology, Data curation. XianChao Jia: Investigation. Ye Gao: Investigation. Yang Jiao: Writing – review & editing, Supervision, Conceptualization.

    This work was supported by the National Natural Science Foundation of China (Nos. 22338005, 21977015).

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2024.110297.


    1. [1]

      C. Leslie, K. Hanna, G. Massimo, et al., Nat. Rev. Immunol. 23 (2023) 787–806. doi: 10.1038/s41577-023-00877-7

    2. [2]

      D. Deborah, H. Justus, E. Shelton, et al., Nat. Rev. Clin. Oncol. 20 (2023) 755–779. doi: 10.1038/s41571-023-00813-7

    3. [3]

      R. Daly, A. Scott, O. Klein, et al., Mol. Cancer 21 (2022) 189. doi: 10.1186/s12943-022-01656-z

    4. [4]

      H. Singh, Y. Li, L. Spurr, et al. Clin. Cancer Res. 27 (2021) 1695–1705. doi: 10.1158/1078-0432.ccr-20-4073

    5. [5]

      X. Ma, M. Mao, J. He, et al., Chem. Soc. Rev. 52 (2023) 6447–6496. doi: 10.1039/d3cs00063j

    6. [6]

      K. Wang, C. Liu, H. Zhu, et al., Coordin. Chem. Rev. 477 (2023) 214946. doi: 10.1016/j.ccr.2022.214946

    7. [7]

      J. Tan, H. Li, L. Zhang, et al., Nat. Commun. 13 (2022) 594. doi: 10.1038/s41467-022-28213-y

    8. [8]

      J. Liu, J. Fraire, S. Smedt, R. Xiong, K. Braeckmans, Small 16 (2020) 2000146. doi: 10.1002/smll.202000146

    9. [9]

      X. Wu, R. Wang, N. Kwon, et al., Chem. Soc. Rev. 51 (2022) 450–463. doi: 10.1039/d1cs00543j

    10. [10]

      Z. Wang, J. Li, J. Chen, et al., Chin. Chem. Lett. 34 (2023) 108507. doi: 10.1016/j.cclet.2023.108507

    11. [11]

      H. Zhu, K. Ma, R. Ruan, et al., Chin. Chem. Lett. 35 (2024) 108536. doi: 10.1016/j.cclet.2023.108536

    12. [12]

      W. Liu, Q. Qiao, J. Zheng, et al. Biosens. Bioelectron. 176 (2021) 112886. doi: 10.1016/j.bios.2020.112886

    13. [13]

      Z. Li, P. Liang, T. Ren, et al., Angew. Chem. Int. Ed. 62 (2023) e202305742. doi: 10.1002/anie.202305742

    14. [14]

      P. Liu, F. Fang, H. Wang, et al., Angew. Chem. Int. Ed. 62 (2023) e202218706. doi: 10.1002/anie.202218706

    15. [15]

      Y. Wang, H. Wu, W. Hu, et al., Adv. Mater. 34 (2022) 2105405. doi: 10.1002/adma.202105405

    16. [16]

      R. Kankala, Adv. Drug Deliv. Rev. 186 (2022) 114270. doi: 10.1016/j.addr.2022.114270

    17. [17]

      H. Wang, P. Liang, L. Zhang, Chin. Chem. Lett. 34 (2023) 108129. doi: 10.1016/j.cclet.2023.108129

    18. [18]

      I. Sterin, J. Hadynski, A. Tverdokhlebova, et al., Adv. Mater. 36 (2024) 2308640. doi: 10.1002/adma.202308640

    19. [19]

      E. Linnane, S. Haddad, F. Melle, et al., Chem. Soc. Rev. 51 (2022) 6065–6086. doi: 10.1039/d0cs01414a

    20. [20]

      C. Zhou, J. Chen, B. Zheng, et al., ACS Appl. Mater. Interfaces 15 (2023) 44731–44741. doi: 10.1021/acsami.3c08936

    21. [21]

      C. Liu, L. Guo, Y. Wang, et al., Coordin. Chem. Rev. 494 (2023) 215332. doi: 10.1016/j.ccr.2023.215332

    22. [22]

      M. Kahlson S. Dixon, Science 375 (2022) 6586.

    23. [23]

      H. Lei, G. Hou, M. Chen, et al. Nano Today 53 (2023) 102033. doi: 10.1016/j.nantod.2023.102033

    24. [24]

      M. Yan, S. Wu, Y. Wang, et al., Adv. Mater. 36 (2024) 2304249. doi: 10.1002/adma.202304249

    25. [25]

      N. Ebrahimi, E. Fardi, H. Ghaderi, et al., Cell. Mol. Life Sci. 80 (2023) 104. doi: 10.1007/s00018-023-04729-4

    26. [26]

      J. Li, Q. Qiao, Y. Ruan, et al. Chin. Chem. Lett. 34 (2023) 108266. doi: 10.1016/j.cclet.2023.108266

    27. [27]

      N. Singer, P. Sánchez-Murcia, M. Ernst, et al., Angew. Chem. Int. Ed. 61 (2022) e202205198. doi: 10.1002/anie.202205198

    28. [28]

      J. Jin, Y. Zhang, J. Zhang, et al., Drug Resist. Updat. 67 (2023) 100929. doi: 10.1016/j.drup.2023.100929

    29. [29]

      M. McTigue, B. Murray, J. Chen, et al., Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 18281–18289. doi: 10.1073/pnas.1207759109

    30. [30]

      Y. More, S. Mollick, S. Saurabh, et al., Small 20 (2024) 2302014. doi: 10.1002/smll.202302014

    31. [31]

      L. Kong, S. Lv, Z. Qiao, et al., Biosens. Bioelectron. 207 (2022) 114188. doi: 10.1016/j.bios.2022.114188

    32. [32]

      J. Zhong, J. Zhou, M. Xiao, et al. Chin. Chem. Lett. 33 (2022) 973–978. doi: 10.1016/j.cclet.2021.07.040

    33. [33]

      H. Yuan, N. Li, W. Fan, et al., Adv. Sci. 9 (2022) 2104374. doi: 10.1002/advs.202104374

    34. [34]

      B. Shen, C. Ma, Y. Ji, et al., ACS Appl. Mater. Interfaces 13 (2021) 8718–8726. doi: 10.1021/acsami.0c19811

    35. [35]

      B. Morozov, F. Gargiulo, S. Ghule, et al., J. Am. Chem. Soc. 146 (2024) 7105–7115. doi: 10.1021/jacs.4c01621

    36. [36]

      J. Xing, Q. Gong, R. Zou, et al., Chin. Chem. Lett. 34 (2023) 107786. doi: 10.1016/j.cclet.2022.107786

    37. [37]

      D. Berndt, D. Glaap, T. Jennings, et al., Angew. Chem. Int. Ed. (2024) e202402616.

    38. [38]

      H. Zhao, N. Li, C. Ma, et al., Chin. Chem. Lett. 34 (2023) 107699. doi: 10.1016/j.cclet.2022.07.042

    39. [39]

      S. Jeon, C. Castillo, V. Nava, et al., Small 20 (2024) 2304588. doi: 10.1002/smll.202304588

    40. [40]

      H. Cheng, C. Wang, Z. Lyu, et al., J. Am. Chem. Soc. 145 (2023) 1216–1226. doi: 10.1021/jacs.2c11053

    41. [41]

      A. Basolo, A. Matrone, R. Elisei, et al., Semin. Cancer Biol. 79 (2022) 197–202. doi: 10.1016/j.semcancer.2020.12.008

    42. [42]

      X. Qi, M. Yang, L. Ma, et al., J. Immunother. Cancer 8 (2020) e001038. doi: 10.1136/jitc-2020-001038

    43. [43]

      L. Tu, C. Li, X. Xiong, et al., Angew. Chem. Int. Ed. (62) 2023 e202301560.

    44. [44]

      C. Li, L. Tu, J. Yang, et al., Chem. Sci. 14 (2023) 2901. doi: 10.1039/d2sc06936a

    45. [45]

      L. Xu, M. Peng, T. Gao, et al., Adv. Sci. 11 (2024) 2306203. doi: 10.1002/advs.202306203

    46. [46]

      R. Chen, W. Li, R. Li, et al, Chin. Chem. Lett. 34 (2023) 107845. doi: 10.1016/j.cclet.2022.107845

    47. [47]

      Y. Xu, C. Li, J. An, et al., Sci China Chem. 66 (2023) 155. doi: 10.1007/s11426-022-1440-2

    48. [48]

      A. Yadav, Z. Zhao, Y. weng, et al., J. Am. Chem. Soc. 145 (2023) 1460–1469. doi: 10.1021/jacs.2c12984

    49. [49]

      H. Yuan, Z. Han, Y. Chen, et al., Angew. Chem. Int. Ed. 60 (2021) 8174–8181. doi: 10.1002/anie.202014959

  • Scheme 1  (a) Fluorescence recovery mechanism of probe SNI. (b) SNI@ZIF-8 cell imaging diagram of targeting tumors.

    Figure 1  (a) Assembly diagram of SNI@ZIF-8. (b) Recognition mechanism of small molecule fluorescent probe. (c) Fluorescence responses of SNI (4 µmol/L) to various concentrations of tyrosine kinase DMSO/HEPES (5.5:4.5, v/v, pH 7.4). Time-dependent probe SNI (4 µmol/L) (red line) and fluorescence response of probe with the addition of VEGFR-2 (black line). F0 is the peak fluorescence intensity of the probe in solvent condition. (d) Fluorescence responses of probe SNI to various interferences and the data were acquired in DMSO/HEPES (5.5:4.5, v/v, pH 7.4) solution. Data are presented as mean ± standard deviation (SD) (n = 3). Stereo views of SNI with VEGFR-2 (PDB: 4AGD). (e) The ITC experiments were performed by an isothermal titration microcalorimeter at atmospheric pressure, giving the Ka and the thermodynamic parameters.

    Figure 2  (a) Dynamic laser light scattering of SNI@ZIF-8 (blue) and ZIF-8 (red) with their scanning electron microscope pictures. Scale bar: 100 nm. (b) N2 quantity and pore volume of ZIF-8 or SNI@ZIF-8. (c) Infrared spectroscopy (IR) spectra of SNI (orange), ZIF-8 (blue), and SNI@ZIF-8 (mazarine). (d) XPS spectra of SNI@ZIF-8, 531.65 eV is O peak of SNI@ZIF-8. (e) The fluorescence intensity of SNI@ZIF-8 incubated with VEGFR-2 in DMSO/HEPES (5.5:4.5, v/v, pH 7.4) solution changed with time (0–70 min), inset shows fluorescence intensity versus the concentrations of SNI. Inset shows the release of SNI in the presence (black) or absence (red) of the enzyme. (f) CD spectra of VEGFR-2 (200 µg/mL) with the increasing addition of SNI from 0 to 1.2 µmol/L. Inset shows CD values at 210 nm versus the concentrations of SNI.

    Figure 3  (a) Flow cytometry treated with different concentrations of SNI and SNI@ZIF-8. (b) Imaging of HT-29 cells treated with 2 µmol/L SNI or 60 µg/mL SNI@ZIF-8. (c) Cell uptake assay by ICP-MS. (d) Relative fluorescence intensity for the HT-29 cells after treatment with gefitinib, erlotinib, axitinib and sorafenib. (e) Hemolysis tests of ZIF-8 and SNI@ZIF-8. Data are presented as mean ± SD (n = 3).

    Figure 4  (a) Imaging diagram of SNI@ZIF-8 at the tumor site. (b) In vivo fluorescence imaging of the HT-29 tumor mouse model at different time interval. The fluorescence signal was collected at 570 nm. (c) Ex vivo image of the heart, liver, spleen, lung, kidney and tumor fluorescence of HT-29 tumor mouse model with the probe SNI@ZIF-8 (4 mg/mL, 100 µL) at different time interval (0, 2, 4 and 6 h). (d) H & E staining maps of major organs tissues of mice treated with SNI, ZIF-8 and SNI@ZIF-8. Scale bar: 200 µm.

  • 加载中
计量
  • PDF下载量:  0
  • 文章访问数:  151
  • HTML全文浏览量:  5
文章相关
  • 发布日期:  2025-06-15
  • 收稿日期:  2024-06-03
  • 接受日期:  2024-07-26
  • 修回日期:  2024-07-24
  • 网络出版日期:  2024-07-26
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章